Inclacumab ELISA Kit

Catalog No.

KDD15102

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD62P has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Inclacumab in the sample competitively binds to the pre-coated protein with biotin-labeled Inclacumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Inclacumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Inclacumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

31.25 - 2,000 ng/mL

Sensitivity

5.67 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	1193.7	283.6	69.5	1022.7	257.8	64.4
Standard deviation	178.3	34.3	13.6	86.6	29.2	12.6
CV (%)	14.9	12.1	19.6	8.5	11.3	19.5

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.

Alternative Names

LC1004-002, RO4905417, CAS: 1256258-86-2

Background

Inclacumab is an IgG4 type human monoclonal antibody that inhibits P-selectin, which functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells. This drug was developed by Genentech/Roche to reduce the inflammation and heart tissue damage that often occurs during heart surgery when opening up clogged arteries. Global Blood Therapeutics is licensed the drug and plants to investigate the effects of the drug on the vaso-occlusive crisis, a painful complication of sickle cell disease as a complement to its lead investigational oral, voxelotor.

A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease., PMID:37436495

Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics., PMID:36342398

Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials., PMID:35760536

Experimental Agents for the Treatment of Atherosclerosis: New Directions., PMID:33633471

Comparative Effectiveness of Anti-Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta-Analysis., PMID:33510581

Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial., PMID:27852589

Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial., PMID:26796402

Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects., PMID:26363899

First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin., PMID:25714598

Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers., PMID:25602360

Advances in clinical cardiology., PMID:25074280

Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies., PMID:23522853

Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial., PMID:23500230

Document Download

Inclacumab ELISA Kit.pdf